280744-09-4 | 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%(HPLC)	in stock	$33.00	$23.00
25mg	98%(HPLC)	in stock	$60.00	$42.00
100mg	98%(HPLC)	in stock	$153.00	$107.00
250mg	98%(HPLC)	in stock	$236.00	$165.00
1g	98%	in stock	$384.00	$269.00

Description

• Catalog Number: AF29312
• Chemical Name: 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
• CAS Number: 280744-09-4
• Molecular Formula: C19H12Cl2N2O2
• Molecular Weight: 371.2168
• MDL Number: MFCD09753369
• SMILES: Clc1ccc(c(c1)Cl)C1=C(C(=O)NC1=O)c1cn(c2c1cccc2)C

Computed Properties

• Complexity: 621
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 3.9

Literature

• Cadmium-induced heme-oxygenase-1 expression plays dual roles in autophagy and apoptosis and is regulated by both PKC-δ and PKB/Akt activation in NRK52E kidney cells.

  Toxicology 20160831

• Effects of Chrysotile Exposure in Human Bronchial Epithelial Cells: Insights into the Pathogenic Mechanisms of Asbestos-Related Diseases.

  Environmental health perspectives 20160601

• Enhancing Beta-Catenin Activity via GSK3beta Inhibition Protects PC12 Cells against Rotenone Toxicity through Nurr1 Induction.

  PloS one 20160101

• Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.

  The Journal of biological chemistry 20150529

• Detrimental effects of Notch1 signaling activated by cadmium in renal proximal tubular epithelial cells.

  Cell death & disease 20140801

• Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.

  Acta pharmacologica Sinica 20140701

• Activation of β-catenin by inhibitors of glycogen synthase kinase-3 ameliorates cisplatin-induced cytotoxicity and pro-inflammatory cytokine expression in HEI-OC1 cells.

  Toxicology 20140605

• Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells.

  The Journal of biological chemistry 20140418

• Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death.

  Cell death & disease 20140301

• PI3K signaling mediates diverse regulation of ATF4 expression for the survival of HK-2 cells exposed to cadmium.

  Archives of toxicology 20140201

• 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

  Toxicology and applied pharmacology 20131101

• The glycogen synthase kinase-3β/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells.

  Toxicology letters 20130412

• A critical role for MAPK signalling pathways in the transcriptional regulation of toll like receptors.

  PloS one 20130101

• Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.

  Journal of medicinal chemistry 20121108

• IL-6 augmented motility of airway epithelial cell BEAS-2B via Akt/GSK-3β signaling pathway.

  Journal of cellular biochemistry 20121101

• WNT/β-catenin-signaling pathway stimulates the proliferation of cultured adult human Sertoli cells via upregulation of C-myc expression.

  Reproductive sciences (Thousand Oaks, Calif.) 20121101

• Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.

  FEBS letters 20121019

• Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3β/β-catenin signaling.

  Toxicology and applied pharmacology 20121015

• Pharmacological inhibition of GSK-3β produces late phase of cardioprotection in hyperlipidemic rat: possible involvement of HSP 72.

  Molecular and cellular biochemistry 20121001

• Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization.

  Biochemical and biophysical research communications 20120914

• Roles of glycogen synthase kinase 3 in Alzheimer's disease.

  Current Alzheimer research 20120901

• Activation of Akt/protein kinase B mediates the protective effects of mechanical stretching against myocardial ischemia-reperfusion injury.

  Journal of veterinary science 20120901

• Ischemic postconditioning mediates cardioprotection via PI3K/GSK-3β/β-catenin signaling pathway in ischemic rat myocardium.

  Shock (Augusta, Ga.) 20120801

• Wnt3a upregulates prostaglandin F2α-stimulated vascular endothelial growth factor synthesis in osteoblasts.

  Molecular medicine reports 20120801

• GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells.

  Molecular cancer research : MCR 20120801

• Glycogen synthase kinase 3β (GSK3β) modulates antiviral activity of zinc-finger antiviral protein (ZAP).

  The Journal of biological chemistry 20120629

• Acute inhibition of GSK causes mitochondrial remodeling.

  American journal of physiology. Heart and circulatory physiology 20120601

• Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice.

  Hepatobiliary & pancreatic diseases international : HBPD INT 20120601

• Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120523

• Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse.

  Behavioural brain research 20120516

• Apoptosis induced by SRC-family tyrosine kinase inhibitors in cultured rat cortical cells.

  Neurotoxicity research 20120401

• Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine.

  Schizophrenia research 20120401

• Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.

  Blood 20120308

• Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms.

  Carcinogenesis 20120301

• Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors.

  Oncogene 20120209

• Phosphorylation of Akt/GSK-3β/eNOS amplifies 5-HT2B receptor blockade mediated anti-hypertrophic effect in rats.

  FEBS letters 20120120

• A pharmacologically-based array to identify targets of cyclosporine A-induced toxicity in cultured renal proximal tubule cells.

  Toxicology and applied pharmacology 20120115

• Muscle FBPase binds to cardiomyocyte mitochondria under glycogen synthase kinase-3 inhibition or elevation of cellular Ca2+ level.

  FEBS letters 20120102

• Ursolic acid from Oldenlandia diffusa induces apoptosis via activation of caspases and phosphorylation of glycogen synthase kinase 3 beta in SK-OV-3 ovarian cancer cells.

  Biological & pharmaceutical bulletin 20120101

• Wnt activation by wild type and mutant myocilin in cultured human trabecular meshwork cells.

  PloS one 20120101

• Inhibition of glycogen synthase kinase 3β ameliorates D-GalN/LPS-induced liver injury by reducing endoplasmic reticulum stress-triggered apoptosis.

  PloS one 20120101

• Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania.

  The international journal of neuropsychopharmacology 20110901

• Glycogen synthase kinase-3β regulates Tyr307 phosphorylation of protein phosphatase-2A via protein tyrosine phosphatase 1B but not Src.

  The Biochemical journal 20110715

• Glycogen synthase kinase 3β in the basolateral amygdala is critical for the reconsolidation of cocaine reward memory.

  Journal of neurochemistry 20110701

• Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation.

  Oncogene 20110526

• GSK3β inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility.

  American journal of physiology. Renal physiology 20110501

• Tumor necrosis factor-α induces increased lung vascular permeability: a role for GSK3α/β.

  European journal of pharmacology 20110425

• The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue.

  Experimental dermatology 20110301

• Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production.

  Journal of neurochemistry 20110301

• Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics.

  Neuroscience 20110203

• The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).

  Bioorganic & medicinal chemistry letters 20110101

• RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity.

  PloS one 20110101

• Dendritic cell maturation occurs through the inhibition of GSK-3β.

  Cellular immunology 20110101

• AP-1 is a component of the transcriptional network regulated by GSK-3 in quiescent cells.

  PloS one 20110101

• Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3β-NF-AT signaling.

  Cell & bioscience 20110101

• Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta.

  PloS one 20110101

• Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome.

  PloS one 20110101

• Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.

  PloS one 20110101

• Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis.

  Neuropharmacology 20101101

• Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing.

  Molecular cell 20101008

• Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells.

  Bioorganic & medicinal chemistry 20100915

• Colchicine-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells.

  Cellular and molecular neurobiology 20100801

• {beta}-Catenin regulates airway smooth muscle contraction.

  American journal of physiology. Lung cellular and molecular physiology 20100801

• Inhibition of glycogen synthase kinase 3beta prevents peroxide-induced collapse of mitochondrial membrane potential in rat ventricular myocytes.

  Clinical and experimental pharmacology & physiology 20100701

• Protein Phosphatase 2a and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100630

• 4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin.

  Journal of cellular and molecular medicine 20100601

• Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload.

  Cardiovascular research 20100601

• Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase.

  American journal of physiology. Lung cellular and molecular physiology 20100601

• Effects of areca nut extract on the apoptosis pathways in human neutrophils.

  Journal of periodontal research 20100601

• Neurites regrowth of cortical neurons by GSK3beta inhibition independently of Nogo receptor 1.

  Journal of neurochemistry 20100601

• Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice.

  Brain research bulletin 20100531

• GSK3 beta regulates myelin-dependent axon outgrowth inhibition through CRMP4.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100421

• Chelation of extracellular calcium-induced cell death was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells.

  Cellular and molecular neurobiology 20100301

• 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis.

  The Journal of pharmacology and experimental therapeutics 20100301

• Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode.

  Journal of medicinal chemistry 20100211

• A new class of molecular targeted radioprotectors: GSK-3beta inhibitors.

  International journal of radiation oncology, biology, physics 20100201

• Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70.

  PloS one 20100101

• Sphingosine kinase-1 is required for toll mediated beta-defensin 2 induction in human oral keratinocytes.

  PloS one 20100101

• Atherosclerosis induced by a high-fat diet is alleviated by lithium chloride via reduction of VCAM expression in ApoE-deficient mice.

  Vascular pharmacology 20100101

• Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway.

  Cell proliferation 20091201

• Regulation of serotonin 1B receptor by glycogen synthase kinase-3.

  Molecular pharmacology 20091201

• Glycogen synthase kinase 3beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization.

  Journal of neurochemistry 20091201

• Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway.

  Molecular pharmacology 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Chronic lithium treatment up-regulates cell surface Na(V)1.7 sodium channels via inhibition of glycogen synthase kinase-3 in adrenal chromaffin cells: enhancement of Na(+) influx, Ca(2+) influx and catecholamine secretion after lithium withdrawal.

  Neuropharmacology 20090901

• The glycogen synthase kinase inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) is a partial agonist of the aryl hydrocarbon receptor.

  Drug metabolism and disposition: the biological fate of chemicals 20090801

• Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.

  European journal of medicinal chemistry 20090601

• Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells.

  Biochimica et biophysica acta 20090601

• The ceiling effect of pharmacological postconditioning with the phytoestrogen genistein is reversed by the GSK3beta inhibitor SB 216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione] through mitochondrial ATP-dependent potassium channel opening.

  The Journal of pharmacology and experimental therapeutics 20090601

• Cocaine-induced hyperactivity and sensitization are dependent on GSK3.

  Neuropharmacology 20090601

• Deregulation of Tpl2 and NF-kappaB signaling and induction of macrophage apoptosis by the anti-depressant drug lithium.

  Cellular signalling 20090401

• TNF-induced activation of pulmonary microvessel endothelial cells: a role for GSK3beta.

  American journal of physiology. Lung cellular and molecular physiology 20090401

• Cadmium toxicity toward autophagy through ROS-activated GSK-3beta in mesangial cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20090301

• Knockin of mutant PIK3CA activates multiple oncogenic pathways.

  Proceedings of the National Academy of Sciences of the United States of America 20090224

• Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

  Neuropharmacology 20090201

• GSK3beta regulates differentiation and growth arrest in glioblastoma.

  PloS one 20090101

• Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation.

  Circulation research 20081024

• Advanced glycation end-product-inhibited cell proliferation and protein expression of beta-catenin and cyclin D1 are dependent on glycogen synthase kinase 3beta in LLC-PK1 cells.

  Archives of biochemistry and biophysics 20080901

• A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

  American journal of physiology. Cell physiology 20080901

• Inhibition of glycogen synthase kinase or the apoptotic protein p53 lowers the threshold of helium cardioprotection in vivo: the role of mitochondrial permeability transition.

  Anesthesia and analgesia 20080901

• Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore.

  The Journal of pharmacology and experimental therapeutics 20080701

• Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?

  Neoplasia (New York, N.Y.) 20080601

• Regulation of Akt mRNA and protein levels by glycogen synthase kinase-3beta in adrenal chromaffin cells: effects of LiCl and SB216763.

  European journal of pharmacology 20080531

• Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion.

  Circulation 20080527

• GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption.

  Journal of applied toxicology : JAT 20080501

• Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3beta: interaction with the MPT pore.

  American journal of hypertension 20080501

• Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion.

  American journal of physiology. Heart and circulatory physiology 20080301

• Inhibitors of GSK-3 prevent corticosterone from inducing COX-1 expression in cardiomyocytes.

  Cardiovascular toxicology 20080101

• The selectivity of protein kinase inhibitors: a further update.

  The Biochemical journal 20071215

• Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration.

  Journal of cellular biochemistry 20071201

• MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta.

  The Journal of biological chemistry 20071019

• Media conditioned by retinal pigment epithelial cells suppress the canonical Wnt pathway.

  Neuroscience letters 20070913

• Cyclosporine A- and FK506-induced apoptosis in PC12 cells.

  Cell biology and toxicology 20070901

• Calmodulin inhibitor-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells.

  Cellular and molecular neurobiology 20070901

• GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion.

  Basic research in cardiology 20070701

• Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway.

  Cancer letters 20070628

• Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.

  Bioorganic & medicinal chemistry 20070601

• Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.

  Biochemical and biophysical research communications 20070309

• Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates.

  Molecular cancer therapeutics 20070301

• An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

  Cancer research 20070101

• Inhibiting glycogen synthase kinase 3beta in sepsis.

  Novartis Foundation symposium 20070101

• Involvement of glycogen synthase kinase-3beta in palmitate-induced human umbilical vein endothelial cell apoptosis.

  Journal of vascular research 20070101

• Thapsigargin-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells.

  Neuroscience letters 20061113

• Effects of glycogen synthase kinase 3beta and cyclin-dependent kinase 5 inhibitors on morphine-induced analgesia and tolerance in rats.

  The Journal of pharmacology and experimental therapeutics 20061101

• The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels.

  Experimental cell research 20061101

• [Glycogen synthase kinase-3beta (GSK-3beta) promotes proliferation of ovarian cancer cells in vitro].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061101

• Modulation of key elements of the Wnt pathway by apple polyphenols.

  Journal of agricultural and food chemistry 20060920

• Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells.

  Journal of agricultural and food chemistry 20060920

• Constitutive activity of glycogen synthase kinase-3beta: positive regulation of steady-state levels of insulin receptor substrates-1 and -2 in adrenal chromaffin cells.

  Brain research 20060919

• A cellular assay for measuring the inhibition of glycogen synthase kinase-3 via the accumulation of beta-catenin in Chinese hamster ovary clone K1 cells.

  Assay and drug development technologies 20060801

• Prevention of rat cortical neurons from prostaglandin E2-induced apoptosis by glycogen synthase kinase-3 inhibitors.

  Neuroscience letters 20060529

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation.

  Shock (Augusta, Ga.) 20060501

• Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells.

  The Journal of biological chemistry 20060224

• Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase.

  Oncogene 20060105

• Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium.

  Journal of molecular and cellular cardiology 20060101

• The Wnt signaling pathway as a target for the treatment of neurodegenerative disorders.

  IDrugs : the investigational drugs journal 20060101

• Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells.

  Cancer research 20051001

• Glycogen synthase kinase 3 controls endochondral bone development: contribution of fibroblast growth factor 18.

  Developmental biology 20050915

• GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat.

  Critical care medicine 20050901

• Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.

  Molecular cancer therapeutics 20050901

• Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.

  Cancer research 20050715

• Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050615

• Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.

  Cancer research 20050301

• Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium.

  Neuroscience 20050101

• Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c.

  The Journal of biological chemistry 20041210

• Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.

  Oncogene 20041014

• Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons.

  European journal of pharmacology 20040924

• Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells.

  European journal of pharmacology 20040714

• Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts.

  Circulation research 20040416

• An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.

  Oncogene 20040401

• Protein kinase CK2 phosphorylates the cell cycle regulatory protein Geminin.

  Biochemical and biophysical research communications 20040319

• Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

  Bioorganic & medicinal chemistry letters 20030915

• Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity.

  Neuroreport 20030806

• Evidence that the dephosphorylation of Ser(535) in the epsilon-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin.

  The Biochemical journal 20021015

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective.

  Circulation research 20020308

• GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity.

  FEBS letters 20011102

• Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death.

  Journal of neurochemistry 20010401

• Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

  Chemistry & biology 20001001

• Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.

  Diabetes 20000201

• Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.

  Diabetes 19990801

• Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

  Proceedings of the National Academy of Sciences of the United States of America 19930815

• Glycogen synthase kinase-3β is involved in ligand-dependent activation of transcription and cellular localization of the glucocorticoid receptor.

  Molecular endocrinology (Baltimore, Md.)